open access

Vol 1, No 3 (2016)
Original paper
Published online: 2016-11-04
Get Citation

Quantitative assessment of metamorphopsia using M-charts and Amsler tests in patients with non-treated central serous chorioretinopathy

Edyta Koman, Dorota Borowicz, Małgorzata Ozimek, Agnieszka Oleszczuk, Katarzyna Nowomiejska, Robert Rejdak
·
Ophthalmol J 2016;1(3):89-92.

open access

Vol 1, No 3 (2016)
ORIGINAL PAPERS
Published online: 2016-11-04

Abstract

INTRODUCTION. The aim of this study is the assessment of the clinical parameters related to metamorphopsia using M-charts and traditional Amsler tests in patients with central serous chorioretinopathy (CSCR).

MATERIA LS AND METHODS. Seventeen eyes of 17 patients were examined with M-charts and Amsler tests, as well as with ocular coherence tomography (OCT) at each of three visits during four months of follow-up. The rate of metamorphopsia detection was 82% with M-charts and 76% with Amsler test.

RESULTS . The vertical metamorphopsia score decreased after four months in nine patients (52.9%), 0.1° on average; increased in two patients (11.8%), mean 0.2°; and there was no change in six patients (35.3%). The horizontal metamorphopsia score decreased in seven patients (41.2%), 0.2° on average, increased in three patients (17.6%), 0.23° on average, and there was no change in seven patients (41.2%).

CONCLUSIONS. M-charts are superior to the traditional Amsler charts in the monitoring of metamorphopsia in patients with CSCR. M-charts are a good diagnostic tool for quantitative assessment of metamorphopsia and monitoring over time in patients with CSCR.  

Abstract

INTRODUCTION. The aim of this study is the assessment of the clinical parameters related to metamorphopsia using M-charts and traditional Amsler tests in patients with central serous chorioretinopathy (CSCR).

MATERIA LS AND METHODS. Seventeen eyes of 17 patients were examined with M-charts and Amsler tests, as well as with ocular coherence tomography (OCT) at each of three visits during four months of follow-up. The rate of metamorphopsia detection was 82% with M-charts and 76% with Amsler test.

RESULTS . The vertical metamorphopsia score decreased after four months in nine patients (52.9%), 0.1° on average; increased in two patients (11.8%), mean 0.2°; and there was no change in six patients (35.3%). The horizontal metamorphopsia score decreased in seven patients (41.2%), 0.2° on average, increased in three patients (17.6%), 0.23° on average, and there was no change in seven patients (41.2%).

CONCLUSIONS. M-charts are superior to the traditional Amsler charts in the monitoring of metamorphopsia in patients with CSCR. M-charts are a good diagnostic tool for quantitative assessment of metamorphopsia and monitoring over time in patients with CSCR.  

Get Citation

Keywords

metamorphopsia, M-charts, central serous chorioretinopathy

About this article
Title

Quantitative assessment of metamorphopsia using M-charts and Amsler tests in patients with non-treated central serous chorioretinopathy

Journal

Ophthalmology Journal

Issue

Vol 1, No 3 (2016)

Article type

Original paper

Pages

89-92

Published online

2016-11-04

Page views

644

Article views/downloads

1297

DOI

10.5603/OJ.2016.0017

Bibliographic record

Ophthalmol J 2016;1(3):89-92.

Keywords

metamorphopsia
M-charts
central serous chorioretinopathy

Authors

Edyta Koman
Dorota Borowicz
Małgorzata Ozimek
Agnieszka Oleszczuk
Katarzyna Nowomiejska
Robert Rejdak

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Publisher: VM Media Group sp. z o.o., Grupa Via Medica, 73 Świętokrzyska St., 80–180 Gdańsk

tel.:+48 58 310 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl